Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Fuji
Harvard Business School
Cerilliant
US Department of Justice
Boehringer Ingelheim
Medtronic
Deloitte

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,699,498

« Back to Dashboard

Which drugs does patent 6,699,498 protect, and when does it expire?

Patent 6,699,498 protects NEUPRO and is included in one NDA.

This patent has thirty patent family members in twenty-two countries.
Summary for Patent: 6,699,498
Title: Transdermal therapeutic systems having improved stability and their production
Abstract:This invention provides for, inter alia, a transdermal therapeutic system comprising at least one therapeutically active substance, which is oxidizable by hydroperoxides, wherein the amount of oxidative degradation of said active substances(s) and the corresponding formation of oxidative degradation products is reduced, which comprises one or more constituents of said transdermal therapeutic system being in contact with said active substance(s), wherein the sum of the peroxide number(s) (PON) of each of said constituents related to their percentage of the whole amount of said constituents as expressed by the formula ##EQU1## where N is the percentage content of the whole amount of said constituents in the TTS, n is the number of said constituents in the TTS, i is the running number PON is the peroxide number of each of the constituents, is not greater than 20.
Inventor(s): Muller; Walter (Neuwied, DE)
Assignee: LTS Lohmann Therapie-Systeme AG (Andernach, DE)
Application Number:09/723,130
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,699,498
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;

Drugs Protected by US Patent 6,699,498

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,699,498

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 57 401Nov 29, 1999
Germany100 54 713Nov 04, 2000

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Covington
Mallinckrodt
Accenture
Express Scripts
Queensland Health
Julphar
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.